A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2004
12/29/2004	WO2004112801A2 Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer
12/29/2004	WO2004112792A1 The medical use of 11,11`-dideoxyverticillin a
12/29/2004	WO2004112778A1 Cisplatin preparation and process for producing the same
12/29/2004	WO2004112764A1 Suppressant of toxicity induced by cancer chemotherapeutic agent and composition of cancer chemotherapeutic agent containing the same
12/29/2004	WO2004112761A2 Stable 5, 10-methylene-tetrahydrofolate pharmaceutical compounds
12/29/2004	WO2004096293A3 Method and device for radiotherapy
12/29/2004	WO2004089964A8 Lipid-regulating agent and use thereof
12/29/2004	WO2004078097A3 Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer
12/29/2004	WO2004076657A3 Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
12/29/2004	WO2004065590A3 Activation and expansion of t cells
12/29/2004	WO2004064743A3 Modified retinoid compounds and their uses
12/29/2004	WO2004032822A3 Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
12/29/2004	WO2004015072A3 Mrbs as modifiers of the rb pathway and methods of use
12/29/2004	WO2003103671A8 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/29/2004	WO2003057146A3 Novel compositions and methods for cancer
12/29/2004	WO2003025200A3 Methods of using 22417, a novel human aminoprotease family member
12/29/2004	WO2003015797A8 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
12/29/2004	WO2002089747A3 Compositions and methods for the therapy and diagnosis of prostate cancer
12/29/2004	WO2002043648A3 Compounds active at the glucocorticoid receptor ii
12/29/2004	WO2000061774A3 Bone morphogenic proteins
12/29/2004	EP1491632A2 Anti-alphavbeta3 humanized monoclonal antibodies
12/29/2004	EP1491555A1 Anti-human hepatoma monoclonal antibody hab18 light/heavy chain variable region gene, and use thereof
12/29/2004	EP1491553A1 Peptides for the treatment of cancer associated with the human papilloma virus (hpv) and other epithelial tumours
12/29/2004	EP1491551A1 Estrone derivative and process for producing the same
12/29/2004	EP1491544A1 Benzo[a]pyrano[3,2-h]acridin-7-one derivatives, processes for their preparation and pharmaceutical compositions thereof
12/29/2004	EP1491538A1 Anti-mitotic agents which inhibit tubulin polymerization
12/29/2004	EP1491534A1 Novel hairpin polyamide
12/29/2004	EP1491524A2 Selective androgen receptor modulators and methods of use thereof
12/29/2004	EP1491236A1 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
12/29/2004	EP1491216A1 Drugs comprising protein forming hollow nanoparticles and therapeutic substance to be transferred into cells fused therewith
12/29/2004	EP1491215A1 Remedies with the use of hollow protein nanoparticles presenting growth factor or the like
12/29/2004	EP1491214A1 Drugs for treating liver diseases with the use of hollow protein nanoparticles
12/29/2004	EP1491211A1 Remedy for glioblastoma
12/29/2004	EP1491210A1 Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
12/29/2004	EP1491208A1 Stabilized liquid polypeptide-containing pharmaceutical compositions
12/29/2004	EP1491206A1 Induction method for cell differentiation
12/29/2004	EP1491201A1 Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides
12/29/2004	EP1491198A1 use of vitamin d derivatives to enhance efficacy of cytotoxic agents
12/29/2004	EP1491192A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
12/29/2004	EP1491188A1 Topical use of valproic acid for the prevention or treatment of skin disorders
12/29/2004	EP1491093A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
12/29/2004	EP1490696A2 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
12/29/2004	EP1490690A2 Novel compositions and methods in cancer associated with altered expression of mcm3ap
12/29/2004	EP1490689A1 Novel compositions and methods in cancer associated with altered expression of prlr
12/29/2004	EP1490688A1 Novel compositions and methods in cancer associated with altered expression of prdm 11
12/29/2004	EP1490519A2 Life sciences business systems and methods
12/29/2004	EP1490500A1 Novel compositions and methods in cancer associated with altered expression of tbx21
12/29/2004	EP1490490A2 Antisense iap nucleobase oligomers and uses thereof
12/29/2004	EP1490474A2 Method for producing pseudo islets
12/29/2004	EP1490407A1 Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
12/29/2004	EP1490405A2 ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
12/29/2004	EP1490403A2 Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use
12/29/2004	EP1490401A1 Vegf peptides and their use
12/29/2004	EP1490393A1 11beta-substituted 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring
12/29/2004	EP1490391A1 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring substituted with a long chain at the 11beta position
12/29/2004	EP1490388A1 Novel compositions and methods in cancer associated with altered expression of kcnj9
12/29/2004	EP1490387A2 A human ribonucleotide reductase m2 subunit
12/29/2004	EP1490386A2 Novel polypeptides and nucleic acids encoding the same
12/29/2004	EP1490374A2 Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
12/29/2004	EP1490373A1 Inhibitors of nucleoside phosphorylases and nucleosidases
12/29/2004	EP1490367A1 Imidazopyridine derivatives as kinase inhibitors
12/29/2004	EP1490365A1 Azaindoles as inhibitors of c-jun n-terminal kinases
12/29/2004	EP1490364A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/29/2004	EP1490356A1 (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
12/29/2004	EP1490355A1 Indolylmaleimide derivatives
12/29/2004	EP1490354A1 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
12/29/2004	EP1490341A1 Novel adamantane derivatives
12/29/2004	EP1490339A1 Novel chalcone derivatives and uses thereof
12/29/2004	EP1490336A1 Piperidine or 8-aza-bicyclo(3.2.1)oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
12/29/2004	EP1490317A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490121A1 Drug delivery particle
12/29/2004	EP1490120A1 Embolization
12/29/2004	EP1490112A1 Method and agent for producing therapeutically active blood compositions
12/29/2004	EP1490110A2 Anti-alpha v beta 6 antibodies
12/29/2004	EP1490109A2 Egfr ligands and methods of use
12/29/2004	EP1490108A2 Drg11-responsive (dragon) gene family
12/29/2004	EP1490102A1 Fuel additive
12/29/2004	EP1490101A1 Methods of enhancing immune induction involving mda-7
12/29/2004	EP1490098A2 Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
12/29/2004	EP1490094A1 Antibody fusion proteins: effective adjuvants of protein vaccination
12/29/2004	EP1490089A1 Peptides selectively lethal to malignant and transformed mammalian cells
12/29/2004	EP1490085A2 Fc receptor homolog, reagents, and uses thereof
12/29/2004	EP1490082A2 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43
12/29/2004	EP1490081A1 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
12/29/2004	EP1490072A1 Novel therapeutical use of agonist ligands specific to g2a receptor
12/29/2004	EP1490070A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
12/29/2004	EP1490065A1 Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
12/29/2004	EP1490064A1 Substituted pyridinones as modulators of p38 map kinase
12/29/2004	EP1490062A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490056A1 N-'4-(2-imino-pyrrolidin-1-yl)phenyl)-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
12/29/2004	EP1490054A2 Hemiasterlin derivatives and uses thereof in the treatment of cancer
12/29/2004	EP1490053A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
12/29/2004	EP1490051A1 Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy
12/29/2004	EP1490050A2 Methods for alzheimer's disease treatment and cognitive enhancement
12/29/2004	EP1490045A1 In vivo use of glutathionone s-transferase activated nitric oxide donors
12/29/2004	EP1489924A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
12/29/2004	EP1343516A4 Analogues of thiocoraline and be-22179
12/29/2004	EP1334094B1 Cholesterol lowering benzo[b]thiophenes and benzo[d]isothiazoles
12/29/2004	EP1289562B1 Novel preparation of hypericin bonded with poly-n-vinylamides
12/29/2004	EP1265891B1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines

1 ... 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 ... 2211